We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

107 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.31% less ownership

Funds ownership: 50.87% → 49.55% (-1.3%)

7% less funds holding

Funds holding: 115 → 107 (-8)

25% less capital invested

Capital invested by funds: $152M → $113M (-$38.5M)

34% less call options, than puts

Call options by funds: $109K | Put options by funds: $164K

47% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 17

Holders
107
Holders Change
-8
Holders Change %
-6.96%
% of All Funds
2.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
33
Reduced
21
Closed
17
Calls
$109K
Puts
$164K
Net Calls
-$55K
Net Calls Change
-$265K

Top Buyers

1
BlackRock
BlackRock
New York
+$1.33M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$556K
3
State Street
State Street
Massachusetts
+$417K
4
Two Sigma Investments
Two Sigma Investments
New York
+$147K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$124K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$1.45M
2
DWM
Destination Wealth Management
California
-$1.42M
3
Deutsche Bank
Deutsche Bank
Germany
-$1M
4
MHP
Manatuck Hill Partners
Connecticut
-$747K
5
LCM
Laurion Capital Management
New York
-$472K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadwood Capital
New York
$61.7M – – –
BlackRock
2
BlackRock
New York
$12.2M +$1.33M +660,653 +11%
Vanguard Group
3
Vanguard Group
Pennsylvania
$9.15M +$556K +276,192 +6%
Axa
4
Axa
France
$4.74M +$31.9K +15,866 +0.6%
State Street
5
State Street
Massachusetts
$4.59M +$417K +206,905 +9%
PGP
6
Prescott General Partners
Florida
$3.81M – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$2.39M +$124K +61,477 +5%
Northern Trust
8
Northern Trust
Illinois
$2.09M +$115K +56,896 +5%
IA
9
IndexIQ Advisors
New York
$1.67M -$14.7K -7,290 -0.8%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$1.53M +$76.7K +38,119 +5%
TCIM
11
TIAA CREF Investment Management
New York
$927K +$7.94K +3,946 +0.8%
Deutsche Bank
12
Deutsche Bank
Germany
$517K -$1M -498,349 -63%
Morgan Stanley
13
Morgan Stanley
New York
$499K +$4.01K +1,990 +0.7%
DCM
14
DAFNA Capital Management
California
$374K – – –
Two Sigma Investments
15
Two Sigma Investments
New York
$366K +$147K +73,230 +56%
Charles Schwab
16
Charles Schwab
California
$359K – – –
Swiss National Bank
17
Swiss National Bank
Switzerland
$338K – – –
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$323K – – –
TA
19
Teachers Advisors
New York
$318K – – –
Renaissance Technologies
20
Renaissance Technologies
New York
$300K -$1.45M -721,004 -81%
California State Teachers Retirement System (CalSTRS)
21
California State Teachers Retirement System (CalSTRS)
California
$282K +$7.5K +3,726 +2%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$214K +$78.3K +38,876 +49%
AllianceBernstein
23
AllianceBernstein
Tennessee
$195K -$3.68K -1,829 -2%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$193K +$72.5K +36,005 +51%
RhumbLine Advisers
25
RhumbLine Advisers
Massachusetts
$187K +$30K +14,891 +17%
1
2 3 4 5

LCTX Hedge Fund Activity: Q2 2018 in Review

107 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2018, worth a combined $113M — down 25% from $152M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of LCTX and 9 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 33 added.

The largest buyer was BlackRock, adding an estimated $1.33M. The largest seller was Renaissance Technologies, cutting an estimated $1.45M.

  • 107 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2018, down from 115 in Q1 2018.
  • Funds reported $113M of Lineage Cell Therapeutics stock for Q2 2018, down 25% quarter-over-quarter.
  • 9 funds opened new Lineage Cell Therapeutics positions in Q2 2018 and 17 closed out, a net change of -8 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2018 was BlackRock, an estimated $1.33M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2018 was Renaissance Technologies, an estimated $1.45M sold.

Based on aggregated 13F filings for Q2 2018.